Biotechnology

Kolon TissueGene's revolutionary knee therapy, once a beacon of hope, fails a pivotal Phase 3 trial, raising questions about its future and the broader field.

With FDA Fast Track and a key ESMO presentation, Nouscom is de-risking its pioneering cancer interception therapy, NOUS-209, for Lynch Syndrome.

Kamada's new plasma supply agreement is more than just revenue; it's a bold validation of its vertical integration strategy in a competitive global market.

A struggling medtech firm and an AI drug developer merge. It's not just a deal; it's a new blueprint for innovation, funded by high-risk capital.

Kibow Biotech's AANP award for its kidney health probiotics isn't just a win for the company; it's a major nod to the growing role of the gut-kidney axis.

VST Capital’s Atlas Healthcare Fund is posting staggering returns by ignoring financial models and reading lab reports. Is this the future of investing?

Arch Biopartners is fast-tracking a novel therapy for diabetic kidney disease, targeting IL-32 to address a massive unmet medical need for millions globally.

Neurizon Therapeutics completes enrollment for its NUZ-001 ALS trial at record speed, accelerating the timeline for potential new treatment data to 2027.

Cellution Biologics' acquisition of SimpliDerm is more than a simple expansion. It's a tale of two diverging strategies in the high-stakes biologics market.

With $9M in new funding, Trellis Bioscience advances a novel antibody that shatters bacterial defenses, offering hope for devastating joint infections.

An award-winning platform is bringing scientific scrutiny to the supplement aisle. Can this push for transparency force a new standard of accountability?

New biotech Rinascera launches with a veteran team and a clinical-stage pipeline. Is its disciplined, asset-acquisition strategy the future for rare diseases?

With its lead gene therapy nearing pivotal data, enGene installs a new chairman with a track record of commercial success, signaling a critical shift from R&D to market readiness.

As OmniAb preps its Q2 results, the real story isn't just the numbers. It's the 'Biological Intelligence' platform reshaping drug discovery from the ground up.

Fresh off a massive Moderna settlement, Arbutus Biopharma expands its patent war against Pfizer and plans a $230M shareholder return, a bold strategic move.

Curative Biotechnology secures a key U.S. patent for a metformin eye-drop, a novel approach that could transform treatment for macular degeneration.

A new biotech collaboration aims to accelerate a novel diagnostic platform, highlighting a growing trend of outsourcing operations to speed innovation in precision medicine.

With mortality rates over 50%, cardiogenic shock has long eluded targeted treatment. Now, a novel antibody from 4TEEN4 gets an FDA fast track.

South Korea's HIGHER Corp. unveils preclinical data for HILO WAVE®, a dual-hyaluronic acid booster that may bypass the inflammatory pathways of competitors.

A groundbreaking NEJM report shows Neutrolis's therapy rapidly reversed severe Lupus symptoms, validating a new, non-immunosuppressive approach.